Amgen (NASDAQ: AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trader Talk

Amgen (AMGN) FOURIER Results 'Good Enough' - CowenMarch 17, 2017 11:23 AM While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman SachsMarch 17, 2017 11:05 AM Baird Incrementally Negative on Amgen (AMGN) Following FOURIER DataMarch 17, 2017 10:40 AM Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety IssuesMarch 17, 2017 9:00 AM